CA2542220A1 - Novel mch receptor antagonists - Google Patents

Novel mch receptor antagonists Download PDF

Info

Publication number
CA2542220A1
CA2542220A1 CA002542220A CA2542220A CA2542220A1 CA 2542220 A1 CA2542220 A1 CA 2542220A1 CA 002542220 A CA002542220 A CA 002542220A CA 2542220 A CA2542220 A CA 2542220A CA 2542220 A1 CA2542220 A1 CA 2542220A1
Authority
CA
Canada
Prior art keywords
group
phenoxy
oxadiazol
alkyl
ethylsulfanylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002542220A
Other languages
English (en)
French (fr)
Inventor
James Ronald Gillig
Michael Dean Kinnick
John Michael Junior Morin
Martinez Antonio Navarro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2542220A1 publication Critical patent/CA2542220A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002542220A 2003-10-22 2004-10-21 Novel mch receptor antagonists Abandoned CA2542220A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51344903P 2003-10-22 2003-10-22
US60/513,449 2003-10-22
PCT/US2004/032314 WO2005040157A2 (en) 2003-10-22 2004-10-21 Novel mch receptor antagonists

Publications (1)

Publication Number Publication Date
CA2542220A1 true CA2542220A1 (en) 2005-05-06

Family

ID=34520102

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002542220A Abandoned CA2542220A1 (en) 2003-10-22 2004-10-21 Novel mch receptor antagonists

Country Status (5)

Country Link
US (1) US20070135485A1 (https=)
EP (1) EP1723126A2 (https=)
JP (1) JP2007510629A (https=)
CA (1) CA2542220A1 (https=)
WO (1) WO2005040157A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100418965C (zh) 2003-08-15 2008-09-17 万有制药株式会社 咪唑并吡啶衍生物
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
CN101309905A (zh) * 2005-08-12 2008-11-19 阿斯利康(瑞典)有限公司 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途
TW200800220A (en) * 2005-10-26 2008-01-01 Boehringer Ingelheim Int New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
US8329704B2 (en) 2005-12-21 2012-12-11 Janssen Pharmaceutica, N.V. Substituted pyrazinone derivatives for use in MCH-1 mediated diseases
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
EP2102208B1 (en) 2006-12-05 2014-04-23 Janssen Pharmaceutica NV Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途
SA109300358B1 (ar) 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
US8586792B2 (en) 2011-12-28 2013-11-19 Divi's Laboratories Ltd. Process for the preparation of 4-iodo-3-nitrobenzamide
US9422238B2 (en) 2012-06-01 2016-08-23 National University Of Singapore ICMT inhibitors
CN104870423A (zh) 2012-11-16 2015-08-26 加利福尼亚大学董事会 用于蛋白质化学修饰的pictet-spengler连接反应
US9310374B2 (en) * 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
KR102783230B1 (ko) 2015-11-09 2025-03-19 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd22 항체-메이탄신 콘쥬게이트 및 그것의 사용 방법
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CR20230325A (es) 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
WO2022265993A1 (en) 2021-06-14 2022-12-22 Scorpion Therapeutics, Inc. Urea derivatives which can be used to treat cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
GB9407447D0 (en) * 1994-04-14 1994-06-08 Glaxo Group Ltd Chemical compounds
US6028052A (en) 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
AU7692696A (en) 1995-12-01 1997-06-27 Novartis Ag Heteroaryl derivatives
AU7626496A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Heteroaryl compounds
WO1997020822A1 (en) 1995-12-01 1997-06-12 Novartis Ag Quinazolin-2,4-diazirines as npy receptor antagonist
DE69720429T9 (de) 1996-02-02 2004-09-23 Merck & Co., Inc. Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
EP0888278B1 (en) 1996-02-02 2003-07-23 Merck & Co., Inc. Antidiabetic agents
EP1011651B1 (en) 1996-02-02 2005-04-27 Merck & Co., Inc. Method of treating diabetes and related disease states
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
WO2002074758A2 (en) * 2001-03-16 2002-09-26 Abbott Laboratories Novel amines as histamine-3 receptor ligands and their therapeutic applications
WO2003087046A1 (en) * 2002-04-09 2003-10-23 7Tm Pharma A/S Novel aminotetraline compounds for use in mch receptor related disorders
CA2484233A1 (en) * 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes

Also Published As

Publication number Publication date
JP2007510629A (ja) 2007-04-26
EP1723126A2 (en) 2006-11-22
US20070135485A1 (en) 2007-06-14
WO2005040157A3 (en) 2006-09-28
WO2005040157A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
CA2542220A1 (en) Novel mch receptor antagonists
RU2077535C1 (ru) Производные бензанилида, способ их получения и фармацевтическая композиция, проявляющая антагонизм к 5-htid рецепторам
US7229987B2 (en) Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
JP4495686B2 (ja) γ−セクレターゼ阻害剤としてのスルファミド
CA2375008C (en) Phenoxypropylamine compounds
US11084784B2 (en) ROR-gamma modulators and uses thereof
JP6586492B2 (ja) 4−アミノメチル安息香酸誘導体
KR101198057B1 (ko) 신규한 n-(2-아미노-페닐)-아미드 유도체
JP6552061B2 (ja) 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用
JP4988591B2 (ja) 新規なmch受容体アンタゴニスト
MXPA05006272A (es) Novedosos antagonistas de receptores de mch.
US20040242633A1 (en) Beta3 adrenergic agonists
EP2493862A1 (en) Imidazole derivatives as ido inhibitors
BR112018002304B1 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
JPWO2000071517A1 (ja) フェノキシプロピルアミン化合物
US20140256740A1 (en) Compounds and methods
JP2011502149A (ja) 疼痛の治療用としてのp2x3受容体アンタゴニスト
US20140155381A1 (en) Compounds and methods
JP2012532914A (ja) テトラゾール誘導体
CA2791162A1 (en) Oxadiazole compounds, their preparation and use
JP2007537286A (ja) Pparモジュレーターとしての化合物および組成物
US20090030038A1 (en) Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor
KR20100135248A (ko) 인돌리논 화합물
TW200946117A (en) Compounds having NPY Y5 receptor antagonistic activity
JP2009538865A (ja) 2−フェニル−5−アミノ−1,3,4−オキサジアゾールおよびニコチン性アセチルコチン受容体リガンドとしてのその使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead
FZDE Dead

Effective date: 20121022